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ABSTRACT
The m7G cap is ubiquitous on RNAPII-transcribed
RNA and has fundamental roles in eukaryotic gene
expression, however its in vivo role in mammals
has remained unknown. Here, we identified the m7G
cap methyltransferase, RNMT, as a key mediator of
T cell activation, which specifically regulates ribo-
some production. During T cell activation, induction
of mRNA expression and ribosome biogenesis drives
metabolic reprogramming, rapid proliferation and dif-
ferentiation generating effector populations. We re-
port that RNMT is induced by T cell receptor (TCR)
stimulation and co-ordinates the mRNA, snoRNA
and rRNA production required for ribosome bio-
genesis. Using transcriptomic and proteomic anal-
yses, we demonstrate that RNMT selectively regu-
lates the expression of terminal polypyrimidine tract
(TOP) mRNAs, targets of the m7G-cap binding pro-
tein LARP1. The expression of LARP1 targets and
snoRNAs involved in ribosome biogenesis is selec-
tively compromised in Rnmt cKO CD4 T cells re-
sulting in decreased ribosome synthesis, reduced
translation rates and proliferation failure. By enhanc-
ing ribosome abundance, upregulation of RNMT co-
ordinates mRNA capping and processing with in-
creased translational capacity during T cell activa-
tion.
INTRODUCTION
T cells have major roles in adaptive immunity; cytotoxic
CD8 T cells directly kill infected or cancerous cells by the
transfer of proteolytic enzymes and CD4 helper T cells co-
ordinate the actions of other immune cells by the secretion
of cytokines and factors. Following development in the thy-
mus, naı̈ve T cells circulate through the blood and reside
in the lymphoid organs, quiescent but poised to respond to
the recognition of an antigen through their cognate T cell
receptor (TCR). Strong TCR signalling drives T cell activa-
tion, inducing cell growth, proliferation and differentiation
into effector T cells. This requires the reprogramming of cel-
lular metabolism (1,2) and reshaping of the proteome (3,4),
which are co-ordinated by global and gene-specific increases
in transcription and translation (5–7). Critical to activation,
T cell receptor (TCR) stimulation induces ribosome biogen-
esis, producing the protein synthesis capacity required for
rapid proliferation and effector molecule synthesis (8–10).
Following transcription, RNA polymerase II (RNAPII)-
transcribed RNAs, including mRNA, miRNA, lncRNA,
snRNA and snoRNA precursors, are modified by the addi-
tion of a 7-methylguanosine (m7G) RNA cap (11,12) (Fig-
ure 1A). m7G cap formation involves cap guanosine addi-
tion to the 5′ end of nascent RNA, catalysed by the cap-
ping enzyme RNGTT (RNA guanylyltransferase and 5′-
phosphatase), followed by cap guanosine N-7 methylation
catalysed by RNMT (RNA guanine-7 methyltransferase)
(12). RNMT has an activating subunit, RAM (RNMT-
activating miniprotein/RAMAC), which increases methyl-
transferase activity and recruits RNA to the complex
(13,14). Most non-coding RNAs lose their m7G cap during
maturation by cleavage or further modification to m2,2,7G
trimethylguanosine.
The m7G cap has fundamental functions; it recruits RNA
processing, modification and translation factors, protects
RNA from degradation and identifies it as self by block-
ing the binding of viral RNA sensing receptors (12,15).
The discovery of regulation of the capping enzymes and
the identification of variants of the cap binding complexes
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Figure 1. RNMT is upregulated following T cell activation (A) m7Gpppm6Am cap structure with methyltransferases. (B) The Rnmt cKO T cell model: mature
and progenitor T cell populations are shown with the stage of Rnmt deletion and ex-vivo activation protocol. (C) Control CD4 T cells were activated, after
2 days IL2 was added. Western blot analysis of RNMT and RAM expression. (D) RNMT expression in 20 h-activated Rnmt cKO (n = 3) and control (n
= 3) CD4 T cells. Equivalent cell numbers analysed. (E, F) Cap methyltransferase activity in 1.6 × 105 control (n = 3) and Rnmt cKO (n = 3) activated
CD4 T cells. GpppG capped RNA was incubated with the T cell extracts for the indicated times and the proportion of caps converted to m7GpppG was
determined. (E) radiograph. (F) quantification. (G) FACS analysis of control (n = 5) and Rnmt cKO (n = 5) thymi. Quantification of single positive (SP)
cells and representative plots displaying live cells. Population names on control plot. Dots indicate biological replicates, lines indicate means, P values from
ANOVA with Sidak’s multiple comparisons test throughout. (H) FACS quantification of CD4 and CD8 T cells in spleens, peripheral lymph nodes (pLN),
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reveals the RNA cap as a key integration point of sig-
nalling pathways and gene expression (12,16–20). Such
co- and post-transcriptional regulation mechanisms are in-
creasingly recognised as integral to immune responses (21).
Here, we report that the m7G cap methyltransferase,
RNMT, is induced during T cell activation and is required
for the substantial increases in RNA production, processing
and translation which support T cell expansion. Unexpect-
edly, RNMT has a gene-specific impact, controlling expres-
sion of a subset of RNAs including the terminal polypyrim-
idine tract (TOP) mRNAs encoding ribosomal proteins, ri-
bosome biogenesis factors and translation factors as well as
several non-coding snoRNAs involved in ribosome biogen-
esis. TOP RNAs are stabilised by a specialised cap binding
protein, La-related protein 1 (LARP1), which has a pref-
erence for binding to m7G-capped TOP RNAs (22–25). We
identified the LARP1 binding sites in naı̈ve CD4 T cells and
found a correlation between cap-adjacent LARP1 binding
and reduced RNA expression in Rnmt cKO CD4 T cells. Ex-
pression of the proteins encoded by LARP1-bound RNAs
were reduced in activated Rnmt cKO CD4 T cells, particu-
larly ribosomal proteins and proteins mediating ribosome
biogenesis and translation. Thus, we demonstrate that the
RNMT RNA regulon co-ordinates the mRNA synthesis
and ribosome biogenesis critical for T cell activation.
MATERIALS AND METHODS
Mice
Rnmt fl/fl mice with loxP sites flanking exon 3 of Rnmt were
sourced from Taconic Artemis Gmbh. CD4-Cre (Tg(Cd4-
cre)1Cwi) (26) mice were gifted by Doreen Cantrell. Mice
were maintained on a C57B6/J background in the Biolog-
ical Resource Unit at the University of Dundee using pro-
cedures approved by the University Ethical Review Com-
mittee and under the authorization of the UK Home Office
Animals (Scientific Procedures) Act 1986.
Preparation of cells
Lymph nodes (inguinal, brachial, axillary, superficial cer-
vical, mesenteric, lumbar, caudal), spleens and thymi were
dissected from mice, and mashed through a 70 m cell
strainer (Falcon) to prepare cell suspensions. Blood was
taken by cardiac puncture (following confirmation of death)
and diluted in RPMI medium, red blood cells were lysed
with ACK buffer (150 mM NH4Cl, 10 mM KHCO3,
0.1 mM Na2EDTA). Cells were counted either using the
BD FACSVerse (BD Biosciences) or Novocyte (Acea Bio-
sciences) flow cytometer, by haemocytometer (Fastread
counting slides from Immune systems) or using AccuCheck
counting beads (Thermo Fisher Scientific) in combination
with a BD LSRFortessa (BD Biosciences) flow cytometer.
Western blotting
For analysis of RPs, LARP1 and RAM in supplemental
figure 1 M T cells were lysed directly in Laemmli buffer
(50 mM Tris pH 6.8, 2% SDS, 10% glycerol, 100 mM DTT,
bromophenol blue). For analysis of RNAPII, RNMT and
RAM, T cells were lysed in F-buffer (10 mM Tris–HCl
pH 7.05, 50 mM NaCl, 0.5% Triton X-10). For RNAPII
analysis, lysates were sonicated 3 × 30 s on a Biorup-
tor (Diagenode) at medium intensity. Equivalent cell num-
bers were resolved by SDS-PAGE. For standard western
blots, proteins were transferred onto PVDF membranes
(Millipore) with Tris-glycine buffer (25 mM Tris, 190 mM
glycine, 20% methanol). For analysis of ribosomal proteins
the higher pH CAPs buffer (10 mM CAPs 20% methanol)
was used. Membranes were incubated with primary an-
tibodies (Supplementary Table S1), followed by the rele-
vant HRP-conjugated secondary antibodies (Supplemen-
tary Table S1) and developed with Pierce Super signal ECL
(Thermo Fisher scientific), visualised with X-ray film or us-
ing an ImageQuant LAS 4000 (GE healthcare). Western
blots were quantified using NIH ImageJ software.
m7GTP binding assay
Jurkat cells were cultured in RPMI media, supplemented
with non-essential amino acids (Gibco) and sodium pyru-
vate (Gibco). Jurkat cell pellets were lysed using Buffer B
(10 mM HEPES pH 7.4, 1 mM MgCl2, 10 mM NaCl, 50
mM NaF, 0.5% NP-40). Lysates were pre-cleared with Pro-
tein A-Sepharose beads (Generon, PCA-125) for 30 min at
4◦C, rotating. Lysate were split into equal parts, each in-
cubated with 40 ul m7GTP-Agarose (Jena Bioscience) or
GTP-Sepharose for 2 h at 4◦C. Beads were washed with
Buffer B. After washes, beads were re-suspended in LDS
sample buffer (Novex) with 0.1 M DTT diluted in Buffer
B. m7GTP and GTP pulldown samples were resolved on the
SDS-PAGE gels with SDS Running Buffer (25 mM Tris, 250
mM glycine, 0.1% SDS), then transferred to PVDF mem-
branes, which were probed with rabbit anti-LARP1 anti-
body (ProteinTech).
Flow cytometry
Cells were incubated with labelled antibodies (Supplemen-
tary Table S1) and FC block (anti CD16/32, Biolegend) in
FACS buffer (PBS + 2% FCS (Gibco)). Dead cells were la-
belled with 0.1 g/ml DAPI or Fixable Viability Dye eFluor
780 (eBioscience). For apoptosis, cells were stained with
annexin V APC (Biolegend) in annexin V buffer (10 mM
HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2, 4 mM KCl,
0.75 mM MgCl2). For translating ribosomes, cells were in-
cubated with 1 ug/ml puromycin for 10 min at 37◦C in
T cell culture medium, stained with Fixable Viability Dye
eFluor 780, fixed with 1% PFA in PBS (Santa Cruz Biotech)
on ice, and permeablised and stained for puromycin and
surface markers in saponin buffer (PBS+ 5% FCS + 0.1%
saponin) (27). For cell cycle analysis, cells were fixed in 4%
PFA, permeablised in ice cold 90% methanol 10% PBS, and
stained with antibodies then 1 g/ml DAPI in FACS buffer.
Data was collected using either a BD FACSVerse, or LSR
Fortessa and analyzed using FlowJo10 (BD).
T cell culture
To measure proliferation, apoptosis, puromycin incorpora-
tion and forward scatter, lymph node cells were cultured in
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+ pen/strep + 50 M 2ME) with 0.5 ug/ml Ultra-LEAF
purified anti-mouse CD3ε antibody (clone 145-2C11, Bi-
olegend), and 0.5 ug/ml Ultra-LEAF purified anti-mouse
CD28 antibody (clone 37.51, Biolegend). 20ng/ml IL-2
(proleukin, Norvatis) was added on day 2. For analysis of
protein or RNA in CD4 T cells, magnet sorted CD4 T
cells were cultured in T cell culture medium on anti-CD3
(5 g/ml)/anti-CD28 (1 g/ml) coated plates.
Preparation of CD4 T cells
To purify T cells, for most experiments CD4 T cells were
magnet sorted using EasySep mouse CD4 T cell isolation
kit (Stemcell Technologies), for the ribosome footprinting
experiment the mouse naı̈ve CD4 T cell kit was used, for
CAP-MAP, eCLIP, and -seq the Miltenyi mouse CD4 T
cell kit was used. For proteomics and naı̈ve T cell RNA se-
quencing analysis, naı̈ve CD4 T cells were FACS sorted us-
ing the BD Influx (BD Biosciences), purities were > 98%.
RNA assays
N-7 cap guanosine methylation assay was performed ac-
cording to (14). The in vivo cap methylation assay was per-
formed according to (28). More details in supplemental ma-
terials.
RNA was extracted using Tri-reagent (Sigma) or Tri-
zol (Thermo Fisher scientific) and quantified by Nanodrop
(Thermo Fisher scientific). For qPCR, cDNA synthesised
using iScript (BioRad), then qPCRs performed on a Bio-
Rad CFX384 using ssoFast Eva Green supermix (Bio-
rad) and primers in Supplementary Table S1. For mRNA
extraction a Dynabeads mRNA DIRECT™ Purification
kit was used on total RNA with two rounds of purifi-
cation. mRNA was quantified using the Qubit RNA HS
Assay Kit (Thermo Fisher scientific). For 3H uridine la-
belling of RNA, cells were cultured with 0.37 MBq [5,6–3H]
uridine/ml medium, RNA and mRNA extracted and scin-
tillation counts measured using Optiphase Hisafe3 scintil-
lation fluid (Perkin Elmer) and a Tri-Carb 4910TR scintil-
lation counter (Perkin Elmer).
For northern blotting, 1 g total RNA was analysed
according to the previous report (29) with methylene
blue staining of 28S and 18S rRNAs for loading con-




ACGCGATTGATCG−3′ (30,31). 3′-end biotin-labelled
oligonucleotides were synthesized by Eurofins Genomics.
DNA qPCR
DNA was isolated from CD4 T cells using a DNA blood
and tissue kit (Qiagen). qPCR was performed as described
for cDNA.
RNA sequencing
Naı̈ve T cell transcriptome libraries were prepared by the
Tayside Centre for Genomic Analysis using an Illumina
Truseq kit with Ribozero Gold rRNA depletion. 20 h acti-
vated T cell cytoplasmic transcriptome and ribosome foot-
print libraries were prepared using the Illumina Truseq
Ribo Profile (mammalian) kit. eCLIP was carried out as
described in the seCLIP protocol with a few modifica-
tions (32). Pseudouridine-seq was carried out according to
the -seq protocol (33). CD4 T cell RNAPII CHIPseq
(RNAPII: GSM1903984, input: GSM1903982) (34), and
RAM knockdown HeLa cell RNAseq (GSE87767) (16),
datasets were obtained from NCBI Geo. Library prepara-
tion methods and analysis are further detailed in supple-
mental materials and methods.
Mass spectrometry
CAP-MAP mass spec analysis was carried out as described
previously. TMT proteomics was performed as described
previously (35). Ribo Mega-SEC was performed as de-
scribed previously (29). Further methods and analyses are
detailed in supplemental materials and methods.
Statistical analysis
Excluding ‘omics’ data, statistical analyses and charts were
generated in Graphpad Prism. Where used, t-tests were
double sided and unpaired.
Further information
Further detailed protocol information is available in the
supplemental materials. Antibodies, primers and other key
reagents are listed in Supplementary Table S1.
RESULTS
RNMT is upregulated following T cell activation
Following T cell activation, major increases in transcrip-
tion and translation are likely to require increased produc-
tion of the m7G cap to protect, process and translate the
nascent mRNA. Consistent with this, we found that the
m7G cap methyltransferase, RNMT, and co-factor, RAM,
were upregulated downstream of T cell receptor (TCR) sig-
nalling, induced using crosslinking antibody stimulation,
and maintained throughout CD4 and CD8 T cell activa-
tion in the presence of the stimulatory cytokine interleukin 2
(IL2) (Figure 1B, C, Supplementary Figure S1A–E). To as-
sess the role of RNMT in T cells, we crossed mice with Rnmt
floxed alleles to mice expressing CD4-Cre to delete Rnmt at
the double positive (DP) stage of T cell development (Fig-
ure 1B, Supplementary Figure S1F). These cells are the de-
velopmental precursors to the mature T cells that are the
subject of this study (26). In Rnmtfl/fl CD4-Cre mice (Rnmt
cKO, conditional knock-out), RNMT protein was gradu-
ally lost during thymic T cell development and was mini-
mal in naı̈ve or activated lymph node CD4 T cells compared
to the equivalent cells in Rnmtfl/fl mice (controls) (Figure
1D, Supplementary Figure S1G–J). Deletion of Rnmt exon
3 in genomic DNA and loss of RNA reads aligning to Rnmt
exon 3 was confirmed in Rnmt cKO naı̈ve CD4 T cells (Sup-
plementary Figure S1K, L). The expression of RNMT and
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was repressed in activated Rnmt cKO CD4 T cells (Supple-
mentary Figure S1M-N) (36). m7G cap methyltransferase
activity was undetectable in Rnmt cKO in activated (Figure
1E, F) or naı̈ve (Supplementary Figure S1O, P) CD4 T cell
extracts, confirming the loss of RNMT protein and the ab-
sence of any entirely redundant m7G cap methyltransferase.
Rnmt cKOs had normal numbers of DP, CD4 single positive
(SP) and CD8 SP in the thymus compared to controls, but
∼50% less CD4 and CD8 T cells in the peripheral lymph
nodes, spleen and blood (Figure 1G-H). The proportions
of central or effector memory CD4 and CD8 T cells were
equivalent in Rnmt cKO mice and controls (Supplementary
Figure S1Q). Thus, loss of Rnmt has a moderate impact on
T cell homeostasis.
Cap guanosine N-7 methylation is reduced in Rnmt cKO T
cells
Although m7G cap methyltransferase activity was minimal
in Rnmt cKO CD4 T cell extracts (Figure 1E-F, Supplemen-
tary Figure S1O, P), it was important to determine the ex-
tent of mRNA and cap synthesis in vivo. The mRNA con-
tent per cell was unchanged in Rnmt cKO naı̈ve CD4 T
cells, but the induction of mRNA synthesis following acti-
vation was impaired suggesting that RNMT and cap for-
mation is more critical for RNA production in activated
T cells (Figure 2A, B). Nevertheless, uridine incorporation
into mRNA was equivalent on a per-mRNA basis at 20
h following activation, indicating comparable net mRNA
synthesis/degradation at this timepoint (Figure 2C). We
determined the rate of endogenous mRNA cap methyla-
tion in activated CD4 T cells by culturing them with 3H-
methionine, which is converted to the methyl donor, S-
adenosyl methionine (SAM), leading to 3H-labelling of
methyltransferase substrates (28). Methylation of internal
nucleotides did not change in Rnmt cKO CD4 T cells com-
pared to controls, consistent with no change in net mRNA
synthesis/degradation (Figure 2D, Supplementary Figure
S2A). Cap methylation, which includes both m7G and first
nucleotide methylation, was reduced by ∼30% in Rnmt cKO
CD4 T cells (Figure 2D, E). Given that we do not expect
first nucleotide methylation to be affected, this indicates a
significant reduction in the rate of m7G formation.
The cap structures present on mRNA from activated
T cells were quantified by CAP-MAP mass spectrome-
try (37). Rnmt cKO CD4 T cells had significantly more
cap structures which lack m7G: GpppGm, Gpppm6Am, and
GpppAm, and significantly less mature m7G-cap struc-
tures: m7GpppCm, m7GpppGm and m7GpppAm than con-
trols (Figure 2F). Our protocols do not detect m7GpppUm.
Over 99% of control CD4 T cell mRNA had a m7G cap
structure, whereas in Rnmt cKOs m7G-caps were reduced
by 28% on mRNAs initiating with guanosine and by 17%
on mRNAs initiating with adenosine (Figure 2G). Thus in
Rnmt cKO CD4 T cells, m7G-caps are synthesised at a lower
rate, their steady state concentration is lower, but the mod-
ification is still abundant, indicating selection for mRNA
bearing a complete m7G cap structure. Interestingly, Rnmt
cKOs had a 35% decrease in mRNA initiating with cyto-
sine, but ∼95% of this mRNA had an m7G cap (Figure 2G,
H). This implies that the incomplete cap generated when
the first transcribed nucleotide is cytosine (GpppCm), is the
least tolerated incomplete cap structure, leading to loss of
RNA initiating with a C on Rnmt deletion.
Rnmt deletion has a gene-specific impact including selective
loss of TOP mRNAs
To determine the impact of Rnmt deletion on RNA ex-
pression we performed RNA sequencing (seq) analysis on
naı̈ve CD4 T cells. Of 11 219 genes which passed analy-
sis thresholds, 753 were significantly reduced and 845 were
significantly increased in Rnmt cKOs compared to controls
(Figure 3A, Supplementary Table S2). Pathway analysis in-
dicated that the downregulated transcripts were enriched
for ribosomal protein genes, with 58 of the 69 genes in
this pathway significantly decreased in Rnmt cKOs (Fig-
ure 3A, Supplementary Figure S2B). Ribosomal protein
(RP) genes were the only significantly enriched pathway
among the RNMT-sensitive genes, so we focussed further
analysis on this group. Differential expression of selected
genes was confirmed by RT-qPCR (Supplementary Figure
S2C). RP transcripts were highly abundant in naı̈ve CD4
T cells: using the reads per kilobase per million (RPKM)
as an approximation of transcript abundance they consti-
tuted ∼27% of the protein coding transcriptome, which re-
duced to ∼18% in Rnmt cKOs (Figure 3B, C). In HeLa
cells, genes with highest RNAPII occupancy have the high-
est sensitivity to knockdown (KD) of RNMT-RAM (16).
Analysis of published RNAPII ChIP data indicated that
RP genes also have high RNAPII occupancy in naı̈ve CD4
T cells (34), however, other transcripts with high RNAPII
occupancy remain unaffected in Rnmt cKO CD4 T cells
(Supplementary Figure S2D), indicating that high RNAPII
is not predictive of RNMT dependence in CD4 T cells.
Furthermore, unlike in HeLa cells, RNAPII CTD (C-
terminal domain) Ser-5 and Ser-2 phosphorylation and net
mRNA synthesis/degradation were not RNMT-dependent
suggesting that transcription is not significantly regulated
through RNMT in CD4 T cells (Figure 2C, Supplementary
Figure S2E, F).
Transcripts encoding RPs and certain translation factors
are members of a family of mRNAs initiating with cytosine
followed by a terminal oligopyrimide (TOP) motif in their
5′ untranslated region (UTR). TOP RNAs bind to a spe-
cialised cap binding protein, La-related protein 1 (LARP1),
which enhances their stability and represses their transla-
tion in MTOR and CDK1-regulated mechanisms that coor-
dinate ribosome biogenesis with cell growth and circadian
rhythms (24,38–45). Canonical cap binding proteins such
as EIF4E of the EIF4F complex and NCBP2 of the CBC
complex bind to caps on all mRNA and as such have a high
specificity for the m7G cap, but little preference for the iden-
tity of the first transcribed nucleotide (46,47). LARP1 is a
specialised cap binding protein which has a >90 fold pref-
erence for TOP RNA (in which C is the first transcribed
nucleotide) over mutated TOP RNA with G as the first
transcribed nucleotide (40). Therefore, we initially focussed
on investigating a potential role for LARP1 in mediating
the impact of RNMT on TOP-RNA expression, although
other cap binding proteins are also likely to have a role in
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Figure 2. Rnmt cKO T cells have reduced mRNA cap methylation and C-initiating mRNA (A) dT-purified mRNA/cell from control (n = 5) and Rnmt
cKO (n = 4) naı̈ve CD4 T cells. Dots represent biological replicates, bars indicate means. P values from Student’s t-test. (B, C) 20 h-activated CD4 T cells
were incubated with 3H uridine for 4 h. mRNA was dT-purified from control (n = 6) and Rnmt cKO (n = 6) cells. (B) mRNA per million cells. (C) CPM
per g mRNA. Dots represent biological replicates, bars indicate means. P values from Student’s t-test. Data combined from two experiments. (D, E) CD4
T cells activated for 20 h were 3H-labelled on methyl groups for 2.25 h. Nucleotides from total RNA from control cells (n = 1), and mRNA from control (n
= 3) and Rnmt cKO cells (n = 4) were resolved by chromatography. Equivalent RNA loaded. (D) Counts per minute (CPM) presented. Elution volumes of
cap dinucleotides and nucleotides determined using standards. Points represent replicates, lines join medians. (E) CPM from cap dinucleotides, fractions
28–34 ml. Dots represent biological replicates, bars indicate mean. P value from Student’s t-test. (F, H) CAP MAP analysis in Rnmt cKO and control 20
hour activated CD4 T cells. (F) Quantitation of cap structures. P values from multiple t-tests corrected with FDR approach * P <0.050, ** P < 0.010, ***P
< 0.001. (G) Proportion of caps with m7G structures. P values from ANOVA with Sidak’s multiple comparisons test. (H) Proportion of caps initiating with
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Figure 3. LARP1 target RP mRNAs are sensitive to loss of Rnmt (A–C) RNAseq analysis of control (n = 3) and Rnmt cKO (n = 3) naı̈ve CD4 T cells. (A)
MA plot of RNA expression. Dots represent genes. Reads per million mapped reads (RPKM) on x-axis. Control and Rnmt cKO samples were compared
using EdgeR exact test and adjusted P-value used. Ribosomal protein genes and other TOP-RNA genes indicated. (B) Distribution of RPKM within all
genes or ribosome protein genes (RPGs) in control and Rnmt cKO naı̈ve CD4 T cell RNAseq data. (C) % of transcripts from RPG calculated using RPKM
as an approximation of transcript abundance. (D) Western blot analysis of LARP1 from Jurkat cell lysates enriched on m7GTP- or GTP-agarose beads.
Data representative of three experiments. (E-I) LARP1 eCLIP of control and Rnmt cKO naı̈ve CD4 T cells. Distribution of reads as counts per million
(CPM) across protein-coding transcripts (E) and non-coding genes (pseudogene and lncRNA) (F) with LARP1 binding sites. (G) Distribution of reads
from LARP1 eCLIP on control naı̈ve CD4 T cells as counts per million (CPM) along target transcripts for three different anti-LARP1 antibodies. (All
other data is Abcam ab86359 antibody which was selected for further analysis). (H) Nucleotide composition surrounding LARP1 binding sites in 5′UTRs.
(I) Reads from anti-LARP1 antibody purified transcripts, isotype control antibody, and size matched input reads aligning to two example LARP1 target
transcripts. Genes annotated, dark yellow = protein coding transcripts, light yellow = non-coding genes, blue = snoRNA. CD4 T cell CAGE data from
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Importantly, other established TOP RNAs were repressed
in Rnmt cKO CD4 T cells (Figure 3A), and RP and other
TOP RNAs were repressed in RNMT-RAM KD HeLa cells
(Supplementary Figure S2G), and in RNMT-compromised
U2OS cells, indicating a conserved mechanism linking TOP
RNA abundance to RNMT activity (16,48).
LARP1 binding is predictive of RNMT dependence
LARP1 has multiple modes of RNA binding. The LA-
module, made up of the LA-motif, PAM2 (PABPC1-
binding) domain and RRM (RNA recognition motif), can
bind to the TOP motif in a cap-independent manner (49).
The LA-module also recognises the polyA tail directly
and through interacting with the polyA-binding protein
PABPC1 (23,24,44,49,50). The DM15 domain is the cap-
binding domain and binds the cap structure and TOP mo-
tif (40,51,52). The DM15 domain binds to the RNA cap
through a pi-stacking mechanism consistent with a pref-
erence for the more positively charged m7G-cap over a
G-capped structure (40,52). Accordingly, we found that
LARP1 had increased interaction with m7GTP over GTP
in vitro (Figure 3D).
In HEK293 cells, PAR-CLIP analysis demonstrated that
LARP1 is bound predominantly to the CDS and 3′UTRs
(39). We sought to identify candidates for cap-dependent
(5′ proximal) LARP1 binding in naı̈ve CD4 T cells by
enhanced crosslinking immunoprecipitation (eCLIP) se-
quencing analysis (Supplementary Figure S3A) (32). In
contrast to the previous report, we found that in CD4 T
cells, the majority of direct LARP1-RNA interactions oc-
curred close to transcript start sites (TSS) in both cod-
ing (Figure 3E) and non-coding (lnc-RNA and pseudo-
genes) targets (Figure 3F). The TSS-adjacent binding pat-
tern was observed with three anti-LARP1 antibodies (Fig-
ure 3G). Overall, we identified 367 LARP1 binding sites
within transcript 5′ UTRs, and these had the expected
pyrimidine rich motif (Supplementary Figure S3B, Fig-
ure 3H, Supplementary Table S3). These TSS-adjacent and
TOP motif-containing binding sites are good candidates for
cap-dependent binding through the DM15 domain. Several
binding sites were also identified in long non-coding RNA
(lncRNA), including snoRNA host genes, and upstream of
or within RP and translation factor pseudogenes (Supple-
mentary Figure S3B) (53). Examples of LARP1 eCLIP data
alignment to individual coding and non-coding genes are
shown in Figure 3I and Supplementary Figure S3C. CAGE
data from the FANTOM5 project are shown as a reference
(54).
LARP1 binding to 5′UTRs, but not other sites, corre-
lated with mRNA repression in the Rnmt cKO CD4 T cells
(Figure 4A). LARP1-bound lncRNA (or snoRNAs derived
from them) and pseudogenes were also repressed in Rnmt
cKO cells (Figure 4A). mRNAs identified as LARP1 tar-
gets included the classical TOP transcripts encoding RPs
and translation factors and additional targets in other path-
ways including signalling, energy metabolism, splicing and
nucleolar functions; amongst these functional groups, RPs,
translation factors and nucleolar proteins were most consis-
tently affected by Rnmt loss (Supplementary Table S3, Fig-
ure 4B). Since LARP1 can bind to the TOP motif via the
La-module in a cap-independent manner, it is likely that
some of the RNMT-insensitive LARP1 targets are bound
through this mechanism, which may have distinct regula-
tory effects (49).
The pattern of LARP1 binding in Rnmt cKO cells was
similar to controls (Figure 3E, F, I, Supplementary Fig-
ure S3C), and notably the expression of LARP1 itself is
not altered in Rnmt cKO CD4 T cells (Supplementary Fig-
ure S4A, B). As discussed earlier, only fully methylated
m7GpppCm, and not GpppCm, was readily detected in Rnmt
cKO CD4 T cells, whereas unmethylated caps on non-TOP
RNAs, GpppAm, Gpppm6Am and GpppGm, were abundant
(Figure 2F, G). These data imply that only TOP-RNAs with
a mature cap (i.e. m7GpppCm) are stable, and GpppCm TOP
mRNA is degraded leading to the selective loss of GpppCm
transcripts in Rnmt cKO CD4 T cells. TOP RNAs with in-
complete cap structures would be predicted to bind less ef-
ficiently to LARP1, which could be responsible for their re-
duced stability in Rnmt cKO cells. In addition, we cannot
rule out the enhanced dependency of TOP RNAs on other
cap binding proteins or associated factors.
Expression of small RNAs and mRNA processing is RNMT-
dependent
Many small RNAs including snRNAs, scaRNAs, snoR-
NAs and their precursors are initially synthesised with a
m7G cap. In addition, several snoRNAs are excised from
the introns of pre-mRNAs or lncRNA hosts, of which we
identified 60 as LARP1-bound (Supplementary Table S3).
50 snoRNAs were detected in the naive CD4 T cell RNAseq
analysis, of which 33 were reduced in Rnmt cKO T cells
(Figure 4C, Supplementary Table S4), these included both
those encoded within LARP1 targets and those that were
not known to be associated with LARP1. All RNAPII-
transcribed snRNAs were repressed in naı̈ve Rnmt cKO
CD4 T cells compared to controls (Figure 4C, Supplemen-
tary Table S4). The snRNA U6 was not repressed, as ex-
pected, since as a RNAPIII-transcript it is synthesised with-
out a m7G cap. Four of the five scaRNAs detected were also
repressed in the Rnmt cKO T cells compared to controls. In-
terestingly, the expression of several snoRNA and snRNAs
were also reduced in RNMT-RAM KD HeLa cells, indicat-
ing a conserved role for RNMT in small RNA expression
(Supplementary Figure S4C) (16).
snoRNAs are involved in the cleavage, methylation and
pseudouridylation of ribosomal RNA, and are required for
ribosome biogenesis (see later). snRNAs are essential con-
stituents of spliceosomes and scaRNAs guide snRNA mod-
ifications. Additionally, a major function of the RNA cap
is to promote splicing of the first intron via an interaction
with cap binding complex (CBC) (55–57). Therefore, we in-
vestigated splicing in naı̈ve CD4 T cells. Rnmt cKO T cells
had a mild defect in first intron splicing resulting in a rela-
tive increase in reads aligning to intron 1 across many genes
(Figure 4D-E). This finding was recapitulated in cytoplas-
mic RNA from activated T cells (Supplementary Figure
S4D-E). The intron 1 bias of the splicing defect in Rnmt
cKOs is consistent with defects in CBC recruitment rather
than a general effect on splicing. Following activation, Rnmt
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Figure 4. Small RNAs are sensitive to loss of Rnmt (A, B) Fold change in RNA expression from Rnmt cKO vs control naı̈ve T cell RNAseq analysis.
LARP1 target transcripts identified by eCLIP. (A) Transcripts grouped by LARP1 binding position and transcript biotype. (B) Transcripts with LARP1
binding to the 5′UTR grouped by functional pathway. (C) sRNA expression in RNAseq analysis of control (n = 3) and Rnmt cKO (n = 3) naı̈ve CD4
T cells. sRNAs are grouped by RFAM family and highlighted if at least one gene overlaps with a LARP1 target, defined as 5′UTR or non-coding RNA
binding. (D, E) Splicing analysis performed using RNAseq data from control (n = 3) and Rnmt cKO (n = 3) naı̈ve CD4 T cells. Exons and introns reads
normalised to total reads for that transcript. Then exon and intron read densities for each transcript compared between controls and Rnmt cKOs. (D)
Violins represent the frequency density. Box plots show median, upper and lower quartiles. Whiskers, 1.5× interquartile range. (E) Pie chart of significantly
altered introns and exons determined using DEXseq. Numbers indicate the number of significant differential splicing events in each group.
trol counterparts (Figure 2A); reduced mRNA processing
linked to loss of CBC interaction is likely to contribute to-
wards this effect.
RNMT is essential for T cell activation
Having established that RNMT has gene-specific impacts
in naı̈ve T cells, we proceeded to determine its role in T cell
activation where transcription, translation and RNMT ac-
tivity are considerably increased (Figure 1B,C). Rnmt cKO
and control lymph node cells were activated ex vivo for
2 days by CD3 and CD28 co-receptor stimulation, followed
by IL2 addition. The high affinity IL2 receptor, CD25, and
type C lectin, CD69, hallmarks of TCR stimulation, were
induced equivalently in Rnmt cKO and control CD4 and
CD8 T cells following activation, indicating that TCR sig-
nalling is intact and induction of certain proteins is RNMT-
independent (58) (Figure 5A, Supplementary Figure S5A).
Control T cells proliferated rapidly following stimulation
whereas Rnmt cKO T cells failed to proliferate, had delayed
cell cycle entry after activation, and exhibited increased
apoptosis (Figure 5B–D, Supplementary Figure S5B, C).
Activated Rnmt cKO T cells had lower forward scatter, a
proxy of cell size, than controls (Figure 5E, Supplementary
Figure S5D). Puromycin incorporation, an indicator of the
number of translating ribosomes, was decreased in Rnmt
cKO T cells following activation (27) (Figure 5F, Supple-
mentary Figure S5E). Thus, the biosynthetic pathways driv-
ing increased protein synthesis, cell growth, and cell cycle
entry are RNMT-dependent.
RNMT has a gene-specific impact on transcript abundance in
activated T cells
We determined the transcriptome-wide effects of Rnmt dele-
tion in CD4 T cells following 24 h of activation: of 10,126
genes analysed, 2874 were significantly repressed and 2726
were significantly increased (Figure 5G, Supplementary Ta-
ble S5). In activated CD4 T cells, the mRNA per cell was
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Figure 5. Rnmt cKO T cells have a defect in protein synthesis following activation (A–F) Control and Rnmt cKO lymph node cells were activated, after 2
days IL2 was added. (A) FACS analysis of CD69 and CD25 in control (n = 5) and Rnmt cKO (n = 5) CD4 T cells. Median fluorescence intensity (MFI)
shown. On dot plots, dots indicate biological replicates, line indicates mean. (B) Proliferation of control (n = 3) and Rnmt cKO (n = 3) CD4 T cells. (C)
FACS analysis of cell cycle of control (n = 5) and Rnmt cKO (n = 5) CD4 T cells, P-values are for % S phase cells. Bar indicates the mean, error bars
indicate standard deviation. (D) Percent of control (n = 5) and Rnmt cKO (n = 5) annexin V+ CD4 T cells. (E) Example FACS plots showing forward
and side scatter of control (1 of n = 5) and Rnmt cKO (1 of n = 5) CD4 T cells following one day of activation. (F) MFI of Puromycin incorporation into
nascent peptides in control (n = 5) and Rnmt cKO (n = 5) CD4 T cells. P-values from ANOVA tests with Sidak’s post test. (G–K) Ribosome footprinting
analysis of cytoplasmic RNA from control (n = 3) and Rnmt cKO (n = 3) 20 h activated CD4 T cells. On scatter plots dots represent genes. Genes with
LARP1 binding to transcript 5′UTR in pink. (G) MA plot of total RNA expression. Reads per million mapped reads (RPKM) on x-axis. Control and
Rnmt cKO samples compared using EdgeR Exact Test. (H) Comparison of fold changes in total RNA and ribosome protected fragment (RPF) RNA.
Differential translation efficiency (TE) in control and Rnmt cKO was calculated using Ribodiff. (I) Venn diagram displaying overlap between differentially
expressed total RNA and RPF RNA, both P < 0.05 with EdgeR exact test. (J) Comparison of fold changes in total RNA and translation efficiency (TE).
(K) Venn diagram displaying overlap between differentially expressed total RNA P < 0.05 with EdgeR exact test, and translation efficiency, P < 0.05 with
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flecting the impact of RNMT on mRNA transcription, pro-
cessing and stability (Figure 2B). Because of this impact
on RNA levels, single gene repression will be underesti-
mated and upregulation overestimated in RNA seq anal-
ysis. LARP1 target mRNAs were repressed in Rnmt cKO
activated CD4 T cells, and pathways analysis revealed de-
creased expression of mRNAs encoding RPs and proteins
involved in fatty acid oxidation and synthesis, the electron
transport chain and TCA cycle, and DNA repair and repli-
cation (Figure 5G, Supplementary Figure S5F). Decreased
expression of genes involved in these biosynthetic and en-
ergy producing pathways is consistent with the decreased
proliferation and delayed cell cycle entry observed.
Activated Rnmt cKO CD4 T cells had fewer translating
ribosomes (Figure 5F), and a proportion of their mRNA
lacked the m7G cap required for efficient translation (Fig-
ure 2F, G). Thus, we investigated if there was a gene-
specific reduction in translation. Ribosome footprinting de-
tects ribosome-bound mRNA (ribosome protected frag-
ments, RPFs), the relative abundance of which approxi-
mates translation efficiency (TE) (59). Since the number of
translating mRNAs and total mRNA abundance are lower
in Rnmt cKOs most mRNA will be translationally repressed
compared to controls. Therefore, we cannot infer absolute
differences in translation, but can compare relative changes
in efficiency of translation, i.e. whether certain mRNAs are
preferentially translated in Rnmt cKOs or whether all are
equally repressed. For the majority of mRNAs, the fold
change in RPFs matched the fold change in mRNA, indi-
cating equivalent TE in Rnmt cKOs compared to controls
(Figure 5H-I). However, in the Rnmt cKO, 732 mRNAs had
a significantly decreased TE, of which the majority had in-
creased total RNA; and 276 mRNAs had a significantly in-
creased TE, of which the majority had decreased total RNA
(Figure 5J, K, Supplementary Table S5). Despite the loss
of RNMT activity (Figure 1E, F), much of the mRNA in
Rnmt cKO CD4 T cells had a m7G cap (Figure 2F, G), how-
ever, the percentage m7G-capped RNA varied depending
on the first transcribed nucleotide. In the Rnmt cKO cells,
RNAs initiating with C, which includes TOP-RNAs, had
the greatest proportion of caps with a m7G structure (Figure
2F, G). We would expect mRNAs with the m7G cap to have
greater translation efficiency due to their greater affinity to
the translation initiation factor EIF4E (46). Accordingly, of
the 276 mRNAs with increased TE in Rnmt cKO, 93 were
LARP1 target (C-capped) mRNAs. Conversely, we predict
that those RNAs that are stable in the absence of a m7G cap
will be translationally repressed mRNA in the Rnmt cKO.
Ribosome protein synthesis is RNMT-dependent in activated
CD4 T cells
We investigated whether deletion of Rnmt had an impact
on the proteome of naı̈ve and activated CD4 T cells us-
ing quantitative mass spectrometry. This revealed few differ-
ences in protein expression in Rnmt cKO naı̈ve T cells com-
pared to controls; of 3874 proteins detected 12 were signif-
icantly increased and 12 were significantly decreased (Fig-
ure 6A, Supplementary Table S6). Although LARP1 target
mRNAs were repressed in these cells, their proteins were
minimally affected (Figures 3A and 6A, B). TOP mRNA
is known to be translationally repressed in naı̈ve T cells,
and thus forms a pre-transcribed pool poised for expres-
sion upon T cell activation (3). Indeed, following activa-
tion, many proteins were expressed in a Rnmt-dependent
manner (Figure 6C, D, Supplementary Table S7). Consis-
tent with decreased protein synthesis and cell size, the pro-
tein content was about 15% lower in Rnmt cKO cells than
controls (Figure 6C, D). From 4495 proteins detected, 838
proteins were significantly decreased and 32 were increased.
Pathway analysis indicated that RPs were the most strongly
repressed proteins, with translation factors, DNA repli-
cation and cholesterol biosynthesis also repressed (Sup-
plementary Figure S6A). Reduced expression of the RPs
RPS3 and RPS19 in the Rnmt cKO activated CD4 T
cells was confirmed (Figure 6E, Supplementary Figure
S6B).
In activated Rnmt cKO CD4 T cells, we found a correla-
tion between LARP1-binding to the transcript 5′UTR and
repression of the protein product (Figure 6D). Thus, al-
though in naı̈ve RNMT cKO T cells the selective repres-
sion of TOP RNAs had minimal impact on protein syn-
thesis, these transcripts were critical for protein expression
following activation. Of LARP1 target transcripts groups,
the most repressed proteins were RPs, translation factors
and nucleolar proteins (Figure 6F). Focussing on the nu-
cleolar proteins which contribute to ribosome biogenesis
(Figure 6G), the Rnmt cKO activated T cells had reduced
expression of the RNAPI component TAF1D, RNAPI/III
component POL1RC and nucleolin (NCL) all of which
promote rRNA transcription (60–62). Components of the
U3 snoRNP which mediates rRNA cleavage, UTP14a and
IMP3 (63,64), the pseudouridine methyltransferase EMG1
and nucleophosmins 1 and 3 were also decreased (65,66).
These ribosome biogenesis factors all have LARP1 binding
sites.
In HeLa cells, RNMT regulates ribosome biogene-
sis through upregulation of c-MYC (67). Notably c-Myc
mRNA was induced rather than repressed on Rnmt dele-
tion in activated CD4 T cells and there was no evidence of
repression of the Myc transcriptional program (Supplemen-
tary Figure S6C). Conversely RNMT expression is depen-
dent on Myc in activated T cells and induction of RNMT is
likely to contribute to the mechanism through which Myc
induces ribosome biogenesis (Supplementary Figure S6D)
(68).
Ribosome biogenesis is RNMT-dependent in activated CD4
T cells
Since the ribosomal proteins, snoRNAs and ribosome bio-
genesis factors were repressed following Rnmt deletion, we
investigated the impact on ribosome biogenesis. Whilst the
total RNA (mostly rRNA) content of naı̈ve CD4 T cells was
unchanged on Rnmt deletion, following activation the RNA
per cell and net rate of total RNA synthesis/decay was re-
duced in Rnmt cKO T cells compared to controls (Figure
7A-C). Activated Rnmt cKO CD4 T cells had lower levels
of monosomes and polysomes than controls, as assessed
by Ribo Mega-SEC profiling (29) (Figure 7D, E). Thus,
RNMT is critical for the induction of ribosome biogenesis
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Figure 6. RNMT promotes expression of ribosome biogenesis factors in activated T cells TMT proteomics analysis of (A, B) control (n = 4) and Rnmt
cKO (n = 3) naı̈ve CD4 T cells; (C, D) control (n = 4) and Rnmt cKO (n = 4) 20 h-activated CD4 T cells. (A, C) MA plot of protein expression. Control and
Rnmt cKO samples compared by linear modelling in Limma using histone protein intensities to normalise expression between samples. Black dashed line
is at Log2 (Rnmt cKO/control) = 0 and blue dashed line on (C) indicates the median Log2(Rnmt cKO/control). (B, D) Fold change in proteins encoded
by LARP1 target transcripts (eCLIP), in Rnmt cKO vs control naı̈ve. Black dashed line is at log2 (Rnmt cKO/control) = 0 and blue dashed line on (D)
indicates the median log2 (Rnmt cKO/control). (E) Western blot analysis of ribosomal proteins in control (n = 4) and Rnmt cKO (n = 4) 20 hour activated
CD4 T cells. (F) Fold change in proteins in Rnmt cKO versus control activated CD4 T cells, proteins encoded by LARP1 target transcripts (eCLIP), defined
here as 5′UTR binding, are grouped by pathway. Black dashed line is at log2 (Rnmt cKO/control) = 0 and blue dashed line indicates the median log2 (Rnmt
cKO/control). (G) Comparison of protein and RNA expression from 20 h activated T cell cytoplasmic RNAseq and TMT proteomics analyses. Nucleolar
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Figure 7. RNMT promotes ribosome biogenesis in activated T cells (A) RNA/cell from control (n = 5) and Rnmt cKO (n = 4) naı̈ve CD4 T cells. Dots
represent biological replicates, bars indicate means. P values from Student’s t-test. (B, C) 20 h activated CD4 T cells were incubated with 3H uridine for
4 h. (B) RNA per million control (n = 4) and Rnmt cKO (n = 4) cells. (C) CPM per g RNA from control (n = 6) and Rnmt cKO (n = 6) cells (data
combined from two experiments). Dots represent biological replicates, bars indicate mean. P values from Student’s t-test. (D, E) Ribo Mega-SEC analysis
of control (n = 3) and Rnmt cKO (n = 3) activated CD4 T cells, equivalent cells were loaded. (D) Polysome profiles. Lines represent biological replicates. (E)
Peak areas for 80S/polysomes, 60S and 40S ribosomes. Dots indicate biological replicates. Line indicates the mean. P values from an ANOVA with Sidak’s
post-test. (F, G) Northern blot analysis of rRNA intermediates in control (n = 3) and Rnmt cKO (n = 3) activated CD4 T cells. (F) Diagram explaining the
fragments and probes. (G) Northern blots. Each column number represents a biological replicate. (H) Pseudouridine ()-seq analysis of control (n = 4) and
Rnmt cKO (n = 4) activated CD4 T cells. PSU-score = (read starts/read coverage) CMC treated/(read starts/read coverage) mock treated for nucleotide
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Having established that ribosome biogenesis was reduced
in Rnmt cKOs we investigated the impact on ribosome qual-
ity control. We characterised the protein content of ribo-
somes in activated Rnmt cKO CD4 T cell ribosomal frac-
tions and found no significant differences in relative abun-
dance of any RP in any ribosomal fraction (Supplementary
Figure S7, Table S8). snoRNAs can either guide pre-rRNA
cleavage, pseuouridylation or ribose 2′O-methlyation and
we found examples of each class to be downregulated in
Rnmt cKO CD4 T cells (Supplementary Table S4). Analysis
of rRNA processing intermediates demonstrated equivalent
rRNA processing in the control and Rnmt cKO activated
CD4 T cells (Figure 7F, G). Pseudouridine ()-seq analysis
of rRNA activated CD4 T cells detected pseudouridine in
75 positions (33), but revealed no differences in the conver-
sion of uridine to pseudouridine in the control and Rnmt
cKO (Figure 7H, Supplementary Table S9). Thus, RNMT
controls the rate, but not the quality of ribosome biogenesis.
In conclusion, we report that during T cell activation,
upregulation of RNMT co-ordinates mRNA capping and
maturation with increased translational capacity by selec-
tively upregulating the proteins and non-coding RNAs in-
volved in ribosome biogenesis.
DISCUSSION
When T cells are activated by interaction with a cognate
antigen, the transition from naı̈ve to activated phenotype
is driven by the induction of biosynthetic pathways. Here,
we identified the m7G cap methyltransferase RNMT as a
key mediator of T cell activation, induced by TCR stim-
ulation. The m7G cap has previously defined biochemical
roles in RNA processing and translation, however, prior to
this study its influence on endogenous cellular transcripts
in mammals had been unclear because the m7G capping en-
zymes, RNGTT and RNMT, are essential for cell viability
in most lineages (69).
An important observation was that although cap guano-
sine N-7 methyltransferase activity was undetectable on
Rnmt deletion, ∼80% mRNA had a complete m7GpppNm
cap in Rnmt cKO T cells. Although by all indicators Rnmt
gene deletion was successful, residual RNMT protein may
be sufficient to methylate a proportion of mRNA caps
aided by recruitment of RNMT to sites of transcription;
these transcripts would be more stable and better processed
compared to RNA with incomplete cap structures (16,70).
Rnmt cKO T cells, however, cannot induce RNMT pro-
tein upon activation where the accelerated production of
nascent RNA transcription is likely to outstrip the cap
methylation capacity of pre-existing, residual RNMT pro-
tein. An alternative explanation for the presence of the
m7GpppNm cap in Rnmt cKO T cells is that there is a par-
tially redundant m7G methyltransferase, although such en-
zymes or activities have not been identified.
Although the m7G cap is ubiquitous on endogenous cel-
lular RNAPII-transcribed RNA, a key finding here is that
the expression of specific RNAs have enhanced dependency
on RNMT, including TOP RNAs. The TOP RNAs are pro-
tected from degradation by interaction with a specialised
m7G-cap binding protein, LARP1. In Rnmt cKO CD4 T
cells, the reduction in TOP transcripts and the reduction in
m7GpppCm capped-RNA (predominantly TOP transcripts)
are proportionate (∼30%), and incompletely methylated
GpppCm structures are rare compared to other incomplete
structures such as GpppGm, implying that GpppCm-capped
RNA is unstable. Thus, the protective relationship between
TOP RNAs and the cap binding protein LARP1 may selec-
tively sensitise them to RNMT loss.
The link between RNMT expression and TOP-RNA ex-
pression is robust, being present in naı̈ve and activated
mouse CD4 T cells as well as human cancer cells. De-
spite this strong correlation between LARP1-RNA binding
and RNMT-dependency, other mechanisms could also con-
tribute to the specification of RNMT-dependent RNAs. For
instance, TOP-RNAs may be more dependent on other cap
binding complexes such as CBC, eIF4E and export com-
plexes for their splicing, co-transcriptional stability or ex-
port, all of which can contribute to RNA stability. How-
ever, unlike LARP1, other analysed cap binding proteins
have no significant binding preference towards the caps of
TOP RNAs over other m7G-capped RNAs. It is also possi-
ble that other factors influence RNMT-dependent expres-
sion of TOP and other RNAs, such as accessibility of RNA
to RNMT or speed of transcription. Although we have fo-
cussed mainly on the RNMT sensitive transcripts in this
study it would also be informative to investigate why many
transcripts are RNMT-insensitive.
TOP RNAs are translationally repressed in naı̈ve T cells,
poised to be expressed in response to activation, permitting
rapid transition to the activated phenotype by accelerating
ribosome biogenesis (3). In unstimulated naı̈ve T cells, al-
though loss of Rnmt affects the transcriptome by altering
the expression of the translationally repressed TOP RNAs
there is little impact on the proteome. Upon activation, T
cells increase their ribosome content, translational capacity,
increase in size and undergo rapid proliferation. RNMT is
required for the expression of TOP-encoded ribosomal pro-
teins and biogenesis factors and in the absence of Rnmt, T
cells fail to increase their translational capacity resulting in
reduced size, delayed cell cycle entry and ultimately apop-
tosis.
Since the role of LARP1 had not been investigated in T
cells previously, we performed eCLIP analysis of LARP1-
RNA interactions in naı̈ve CD4 T cells to identify LARP1
target RNAs and map their site of interaction. In T cells,
the majority of LARP1 binding occurred close to the TSS
in both coding and non-coding RNAs, consistent with cap-
dependent interactions through the DM15 domain. LARP1
can associate with the polyA tail either directly or through
PABPC1 (23,24,44,49,50); our data suggests that most con-
tacts with the 3′ end of RNAs would be indirect in T cells,
however, direct binding to the polyA tail could potentially
still be important for the initiation of this interaction. Not
all the LARP1 targets identified were repressed by loss of
Rnmt. LARP1 can also bind to the TOP motif through the
LA-module in a cap-independent manner (49), which may
have distinct regulatory effects, or these transcripts may re-
cruit other RNA binding proteins that stabilise them (71–
73). Interestingly, we also detected LARP1 binding to RP
and translation factor pseudogenes. Although under cer-
tain conditions, these pseudogenes could potentially act as








undee user on 22 June 2021
Nucleic Acids Research, 2021 15
for LARP1 binding, in naı̈ve CD4 T cells the pseudogene
expression and LARP1 eCLIP read counts were much lower
than their protein-coding counterparts.
Since the ribosomal proteins (RPs) were the most re-
pressed functional group in our proteomics analysis of ac-
tivated Rnmt cKO CD4 T cells, we focussed on ribosome
biogenesis for this study. Ribosomes and translation factors
are the canonical targets of LARP1, however, there were
also LARP1 targets identified in metabolic pathways, splic-
ing, protein processing and cell signalling. Some of these
targets are novel and some have been identified as TOP
RNAs in previous studies (74–76), or as transcripts whose
translation is sensitive to MTOR pathway inhibition (77),
a feature of TOP-RNA regulation. Co-regulation of trans-
lation, metabolism and cell signalling may integrate these
co-dependent processes. The best characterised regulator
of LARP1 is MTOR, a serine/threonine kinase that inte-
grates signals from external and internal stimuli such as
mitogens and nutrient availability (22,78,79). MTOR phos-
phorylates LARP1 adjacent to the DM15 domain, reducing
its cap-binding to allow more efficient translation of TOP
RNAs (24,42,45). We propose that RNMT functions up-
stream of this mechanism since efficient cap methylation al-
lows LARP1 to stabilise a pool of TOP mRNA ready to be
translated upon mitogenic stimuli such as TCR signalling
in T cells.
In addition to affecting TOP RNA expression, RNMT
has roles in non-coding RNA expression and mRNA pro-
cessing, specifically in splicing out the first intron, a CBC-
dependent process (55–57). snRNAs were repressed in
Rnmt cKO CD4 T cells, probably due to destabilisation
of those that do not gain a complete tri-methylguanosine
cap structure, since the un-capped snRNA U6 is unaf-
fected. Rnmt cKO CD4 T cells also had reduced expres-
sion of several snoRNAs. Capped snoRNAs interact with
CBC to recruit snoRNA biogenesis factors, indicating a
potential mechanism for their repression in Rnmt cKOs
(80,81). Intron-derived snoRNAs are not capped so do
not interact directly with CBC, however, it is possible that
they recruit snoRNA biogenesis factors through the CBC
prior to splicing. We identified LARP1 binding sites in 10
lncRNAs and 50 mRNAs that host snoRNAs, and one
snoRNA, Snord104. LARP1 binding could have an impact
on snoRNA host stability or processing, but but changes
were also observed in snoRNAs whose hosts were not iden-
tified as LARP1 targets.
To conclude, we discovered that RNMT has a fundamen-
tal role in upregulating the expression of a TOP RNA reg-
ulon, driving ribosome biogenesis during T cell activation.
Ribosome biogenesis is critical for proliferation during T
cell activation and has important roles in other cells in-
cluding driving inappropriate cell proliferation in cancerous
cells where we have also observed a link between RNMT
and TOP RNAs (8,9,82). Through the selective dependence
of TOP RNA and snoRNA on RNMT, ribosome biogene-
sis is coordinated with the generation of m7G capped tran-
scripts during T cell activation.
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